# Cocrystal Pharma, Inc.: financial statements, quarterly

COCP · Nasdaq · CIK 1412486 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cocp.md) · [Financials](/companies/cocp/financials.md) · [Filings](/companies/cocp/filings.md) · [Insiders](/companies/cocp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cocp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [225](/filings/0001493152-26-023377.md) | [105](/filings/0001493152-26-037573.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [4,194](/filings/0001493152-24-044978.md) | [4,267 d](/filings/0001641172-25-001496.md) | [2,950](/filings/0001641172-25-010539.md) | [4,308](/filings/0001641172-25-023728.md) | [3,242](/filings/0001493152-25-022581.md) | [2,037 d](/filings/0001493152-26-013838.md) | [1,360](/filings/0001493152-26-023377.md) | [1,122](/filings/0001493152-26-037573.md) | [954](/filings/0001493152-25-022581.md) | [1,619 d](/filings/0001493152-26-013838.md) | [1,371](/filings/0001493152-26-023377.md) | [2,142](/filings/0001493152-26-037573.md) |
| Operating income | $k | [(4,443)](/filings/0001493152-24-044978.md) | [(4,666) d](/filings/0001641172-25-001496.md) | [(4,158)](/filings/0001641172-25-010539.md) | [(5,448)](/filings/0001641172-25-023728.md) | [(5,042)](/filings/0001493152-25-022581.md) | [(3,230) d](/filings/0001493152-26-013838.md) | [(2,341)](/filings/0001493152-26-023377.md) | [(2,108)](/filings/0001493152-26-037573.md) | [(2,089)](/filings/0001493152-25-022581.md) | [(2,481) d](/filings/0001493152-26-013838.md) | [(2,356)](/filings/0001493152-26-023377.md) | [(3,184)](/filings/0001493152-26-037573.md) |
| Interest expense | $k | [(320)](/filings/0001493152-23-040322.md) | [(180) d](/filings/0001493152-24-011613.md) | [(220)](/filings/0001493152-24-018787.md) | [(151)](/filings/0001641172-25-023728.md) | [(111)](/filings/0001493152-25-022581.md) | [(55.0) d](/filings/0001493152-26-013838.md) | [(37.0)](/filings/0001493152-26-023377.md) | [(28.0)](/filings/0001493152-26-037573.md) | [(22.0)](/filings/0001493152-25-022581.md) | [(47.0) d](/filings/0001493152-26-013838.md) | [(22.0)](/filings/0001493152-26-023377.md) | [(10.0)](/filings/0001493152-26-037573.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001493152-24-044978.md) | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001493152-26-023377.md) | [0.0 d](/filings/0001493152-26-037573.md) |
| Net income | $k | [(4,165)](/filings/0001493152-24-044978.md) | [(4,464) d](/filings/0001641172-25-001496.md) | [(3,956)](/filings/0001493152-25-022581.md) | [(5,343)](/filings/0001493152-25-022581.md) | [(4,939)](/filings/0001493152-25-022581.md) | [(3,266) d](/filings/0001493152-26-013838.md) | [(2,301)](/filings/0001493152-26-037573.md) | [(2,055)](/filings/0001493152-26-037573.md) | [(2,049)](/filings/0001493152-25-022581.md) | [(2,426) d](/filings/0001493152-26-013838.md) | [(2,299)](/filings/0001493152-26-037573.md) | [(3,164)](/filings/0001493152-26-037573.md) |
| Diluted EPS | $ per share | [(0.41)](/filings/0001493152-24-044978.md) | not reported | [(0.39)](/filings/0001641172-25-010539.md) | [(0.53)](/filings/0001641172-25-023728.md) | [(0.49)](/filings/0001493152-25-022581.md) | not reported | [(0.23)](/filings/0001493152-26-023377.md) | [(0.20)](/filings/0001493152-26-037573.md) | [(0.19)](/filings/0001493152-25-022581.md) | not reported | [(0.17)](/filings/0001493152-26-023377.md) | [(0.23)](/filings/0001493152-26-037573.md) |
| Basic EPS | $ per share | [(0.41)](/filings/0001493152-24-044978.md) | not reported | [(0.39)](/filings/0001641172-25-010539.md) | [(0.53)](/filings/0001641172-25-023728.md) | [(0.49)](/filings/0001493152-25-022581.md) | not reported | [(0.23)](/filings/0001493152-26-023377.md) | [(0.20)](/filings/0001493152-26-037573.md) | [(0.19)](/filings/0001493152-25-022581.md) | not reported | [(0.17)](/filings/0001493152-26-023377.md) | [(0.23)](/filings/0001493152-26-037573.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [29.7](/filings/0001493152-23-040322.md) | [26.4](/filings/0001641172-25-001496.md) | [21.8](/filings/0001493152-24-018787.md) | [18.1](/filings/0001493152-24-031877.md) | [13.0](/filings/0001493152-24-044978.md) | [9.9](/filings/0001493152-26-013838.md) | [6.9](/filings/0001641172-25-010539.md) | [4.8](/filings/0001641172-25-023728.md) | [7.7](/filings/0001493152-25-022581.md) | [7.0](/filings/0001493152-26-013838.md) | [4.7](/filings/0001493152-26-023377.md) | [2.2](/filings/0001493152-26-037573.md) |
| Current assets | $m | [32.2](/filings/0001493152-23-040322.md) | [29.1](/filings/0001641172-25-001496.md) | [24.5](/filings/0001493152-24-018787.md) | [19.7](/filings/0001493152-24-031877.md) | [14.3](/filings/0001493152-24-044978.md) | [11.6](/filings/0001493152-26-013838.md) | [8.8](/filings/0001641172-25-010539.md) | [6.8](/filings/0001641172-25-023728.md) | [8.8](/filings/0001493152-25-022581.md) | [8.1](/filings/0001493152-26-037573.md) | [5.9](/filings/0001493152-26-023377.md) | [3.2](/filings/0001493152-26-037573.md) |
| Total assets | $m | [32.6](/filings/0001493152-23-040322.md) | [31.3](/filings/0001641172-25-001496.md) | [26.5](/filings/0001493152-24-018787.md) | [21.6](/filings/0001493152-24-031877.md) | [16.2](/filings/0001493152-24-044978.md) | [13.5](/filings/0001493152-26-013838.md) | [10.7](/filings/0001641172-25-010539.md) | [8.5](/filings/0001641172-25-023728.md) | [10.4](/filings/0001493152-25-022581.md) | [9.7](/filings/0001493152-26-037573.md) | [7.4](/filings/0001493152-26-023377.md) | [4.6](/filings/0001493152-26-037573.md) |
| Current liabilities | $m | [1.9](/filings/0001493152-23-040322.md) | [3.3](/filings/0001641172-25-001496.md) | [2.4](/filings/0001493152-24-018787.md) | [2.7](/filings/0001493152-24-031877.md) | [1.9](/filings/0001493152-24-044978.md) | [2.4](/filings/0001493152-26-013838.md) | [1.9](/filings/0001641172-25-010539.md) | [1.8](/filings/0001641172-25-023728.md) | [1.5](/filings/0001493152-25-022581.md) | [2.2](/filings/0001493152-26-037573.md) | [2.2](/filings/0001493152-26-023377.md) | [2.6](/filings/0001493152-26-037573.md) |
| Total liabilities | $m | [1.9](/filings/0001493152-23-040322.md) | [4.9](/filings/0001641172-25-001496.md) | [4.0](/filings/0001493152-24-018787.md) | [4.2](/filings/0001493152-24-031877.md) | [3.5](/filings/0001493152-24-044978.md) | [3.9](/filings/0001493152-26-013838.md) | [3.4](/filings/0001641172-25-010539.md) | [3.2](/filings/0001641172-25-023728.md) | [2.8](/filings/0001493152-25-022581.md) | [3.4](/filings/0001493152-26-037573.md) | [3.3](/filings/0001493152-26-023377.md) | [3.6](/filings/0001493152-26-037573.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [30.7](/filings/0001493152-24-044978.md) | [26.4](/filings/0001493152-26-013838.md) | [22.6](/filings/0001493152-25-022581.md) | [17.4](/filings/0001493152-25-022581.md) | [12.7](/filings/0001493152-25-022581.md) | [9.5](/filings/0001493152-26-037573.md) | [7.3](/filings/0001493152-26-037573.md) | [5.3](/filings/0001493152-26-037573.md) | [7.7](/filings/0001493152-25-022581.md) | [6.3](/filings/0001493152-26-037573.md) | [4.1](/filings/0001493152-26-037573.md) | [1.0](/filings/0001493152-26-037573.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,681) d](/filings/0001493152-24-044978.md) | [(3,326) d](/filings/0001641172-25-001496.md) | [(4,503)](/filings/0001641172-25-010539.md) | [(3,699) d](/filings/0001641172-25-023728.md) | [(5,123) d](/filings/0001493152-25-022581.md) | [(3,160) d](/filings/0001493152-26-013838.md) | [(2,939)](/filings/0001493152-26-023377.md) | [(2,155) d](/filings/0001493152-26-037573.md) | [(1,362) d](/filings/0001493152-25-022581.md) | [(1,736) d](/filings/0001493152-26-013838.md) | [(2,340)](/filings/0001493152-26-023377.md) | [(2,516) d](/filings/0001493152-26-037573.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001493152-24-044978.md) | [59.0 d](/filings/0001641172-25-001496.md) | [8.0](/filings/0001641172-25-010539.md) | [0.0 d](/filings/0001641172-25-023728.md) | [0.0 d](/filings/0001493152-25-022581.md) | [0.0 d](/filings/0001493152-26-013838.md) | not reported | not reported | not reported | [0.0 d](/filings/0001493152-26-013838.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.1](/filings/0001493152-23-040322.md) | [8.1](/filings/0001493152-24-018787.md) | [10.1](/filings/0001493152-24-031877.md) | [10.2](/filings/0001493152-24-044978.md) | [10.2](/filings/0001641172-25-010539.md) | [10.2](/filings/0001641172-25-023728.md) | [10.2](/filings/0001493152-25-022581.md) | [10.2](/filings/0001493152-26-023377.md) | [10.2](/filings/0001493152-26-037573.md) | [11.0](/filings/0001493152-25-022581.md) | [13.8](/filings/0001493152-26-023377.md) | [13.8](/filings/0001493152-26-037573.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 19,263,200 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037573.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.